KoBioLabs Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 57

Employees

  • Stock Symbol
  • 348150

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.02
  • (As of Friday Closing)

KoBioLabs General Information

Description

KoBioLabs Inc is a biotechnology company focused on Microbiome therapeutics. The main business of the company is the development of therapeutics and health functional foods based on human microbiome technology.

Contact Information

Website
www.kobiolabs.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Suite 745-1 Building 220
  • 1 Gwanak-ro
  • Seoul, Gwanak 08826
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
LOHAS & Wellness, Life Sciences
Corporate Office
  • Suite 745-1 Building 220
  • 1 Gwanak-ro
  • Seoul, Gwanak 08826
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KoBioLabs Stock Performance

As of 13-Nov-2026, KoBioLabs’s stock price is $2.02. Its current market cap is $39.1M with 19.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.02 $2.00 $1.60 - $5.81 $39.1M 19.4M 19.4K -$0.17

KoBioLabs Financials Summary

As of 30-Jun-2026, KoBioLabs has a trailing 12-month revenue of $52M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 31,715 64,732 54,376 93,993
Revenue 51,961 48,689 50,100 25,346
EBITDA (1,957) (3,673) (2,089) (11,387)
Net Income (3,310) (4,448) (3,883) (10,595)
Total Assets 59,641 63,372 69,313 88,946
Total Debt 10,876 9,562 11,229 14,196
Public Fundamental Data provided by Morningstar, Inc. disclaimer

KoBioLabs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore KoBioLabs‘s full profile, request access.

Request a free trial

KoBioLabs Patents

  • 122

    Total Documents Applications and Grants

  • Total Patents Families

  • 52

    Granted

  • 31

    Pending

  • Expiring in next 12 mo

KoBioLabs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026142280-A1 Bifidobacterium animalis strain and use thereof Pending 23-Dec-2024
WO-2026071804-A1 Bifidobacterium stercoris strain and uses thereof Pending 27-Sep-2024
WO-2026054539-A1 Microbiome-derived extracellular vesicles and use thereof Pending 04-Sep-2024
WO-2025226098-A1 Lactococcus lactis strain and uses thereof Pending 26-Apr-2024
WO-2025159590-A1 Bifidobacterium longum subsp. infantis strain and immunity enhancement uses thereof Pending 26-Jan-2024 C12N1/205
To view KoBioLabs’s complete patent history, request access »

KoBioLabs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KoBioLabs Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore KoBioLabs‘s full profile, request access.

Request a free trial

KoBioLabs Investments (2)

KoBioLabs’s most recent deal was a Joint Venture with WeBiom. The deal was made on 01-Mar-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
WeBiom 01-Mar-2022 Joint Venture Other Consumer Non-Durables
Genexine (Land and Building Asset in Seongnam, South Korea) 24-Jan-2022 Corporate Asset Purchase Buildings and Property
To view KoBioLabs’s complete investments history, request access »

KoBioLabs ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view KoBioLabs’s complete esg history, request access »

KoBioLabs FAQs

  • When was KoBioLabs founded?

    KoBioLabs was founded in 2014.

  • Where is KoBioLabs headquartered?

    KoBioLabs is headquartered in Seoul, South Korea.

  • What is the size of KoBioLabs?

    KoBioLabs has 57 total employees.

  • What industry is KoBioLabs in?

    KoBioLabs’s primary industry is Drug Discovery.

  • Is KoBioLabs a private or public company?

    KoBioLabs is a Public company.

  • What is KoBioLabs’s stock symbol?

    The ticker symbol for KoBioLabs is 348150.

  • What is the current stock price of KoBioLabs?

    As of 13-Nov-2026 the stock price of KoBioLabs is $2.02.

  • What is the current market cap of KoBioLabs?

    The current market capitalization of KoBioLabs is $39.1M.

  • What is KoBioLabs’s current revenue?

    The trailing twelve month revenue for KoBioLabs is $52M.

  • What is KoBioLabs’s annual earnings per share (EPS)?

    KoBioLabs’s EPS for 12 months was -$0.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process